A 70-year-old client with a 75 mcg/hour fentanyl transdermal patch developed respiratory depression at home. EMS administered nasal naloxone 4 mg with restoration of breathing. On ED arrival 45 minutes later, the client is again becoming drowsy with RR 9. Which intervention does the nurse anticipate to prevent ongoing renarcotization?

Long-acting opioids — fentanyl transdermal patch (depot remains 12 to 24 hours after removal), methadone (half-life 15 to 60 hours), sustained-release oxycodone or morphine, and the ongoing presence of an unresolved exposure source (intact patch, illicit fentanyl analog) — outlast a single naloxone dose. Naloxone half-life is short (30 to 90 minutes), so renarcotization (return of respiratory depression) is expected. Hospital management: (1) eliminate ongoing opioid source — remove and dispose of any fentanyl patch and clean the skin to remove residual drug, stop infusions, gather history of any other opioid use; (2) repeat IV naloxone titration as in Q2; (3) initiate a continuous IV naloxone infusion typically calculated as two-thirds of the effective bolus dose given over the previous hour, with hourly reassessment and titration; (4) monitor RR, SpO2, continuous capnography, sedation (POSS), and BP for at least 12 to 24 hours after the patch removal because of depot effect; for methadone overdose monitor longer (24 to 48 hours); (5) transition to subcutaneous naloxone or extended discharge plan if applicable; (6) address pain plan because opioid abrupt cessation will cause withdrawal and pain — multimodal alternatives, slower opioid titration, addiction medicine consult if applicable; (7) document and event report. Waiting, applying a new patch, or discharging on a single nasal dose are unsafe.

Long-acting opioid plus short-acting naloxone equals predictable renarcotization. Remove the source, repeat boluses, start an infusion, monitor for 12 to 24 hours.